XPENG-MOTORS
20.5.2020 01:19:51 CEST | Business Wire | Press release
Xpeng Motors, a leading electric vehicle and technology company, today announced that it has received the official production license from China’s Ministry of Industry and Information Technology for its new own-built, wholly-owned factory, the Zhaoqing Xpeng Motors Intelligent Industrial Park in Guangdong Province.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200519005994/en/
The approval will accelerate the production of the super-long range sports sedan Xpeng P7, the company’s second production model, ensuring customer deliveries scheduled for 2Q 2020.
“The Zhaoqing manufacturing plant is an essential component of our vision to build a smart mobility ecosystem, from in-house R&D to smart manufacturing to customer services. Obtaining the production approval for the plant will hasten our progress in producing and delivering best-in-class products and services for our customers,” said He Xiaopeng, Chairman and CEO of Xpeng Motors.
“Our success in completing the Zhaoqing plant and rolling out our new P7 smart sedan despite the COVID-19 related challenges is further validation of the strength and robustness of our organization,” He said. The company has secured a sufficient stock of essential parts to ensure smooth manufacturing despite the disruption caused by the COVID-19 pandemic.
Located in Guangdong Province, the home-base of Xpeng Motors, the new Zhaoqing plant has a planned total area of 3,000 acres (2 million square meters), with vehicle production facilities covering some 1,500 acres (1 million square meters). Around 900 acres (600,000 square meters) of it has already been completed in the first phase.
After the foundation-laying in December 2017, the factory construction was completed in September 2019. Since then rigorous pre-production testing and small-scale trial production runs have verified the entire manufacturing process.
The Zhaoqing plant contains five workshops to cover the essential smart manufacturing functions, including stamping, welding, painting, assembly and battery pack production, as well as one battery assembly line, and is capable of manufacturing four different models. Serviced by 264 intelligent industrial robots, the Zhaoqing plant also incorporates dynamic test tracks covering 18 different types of test roads, and testing facilities for NVH, braking, vehicle seals and automatic parking systems.
The Zhaoqing plant is built in accordance with Industry 4.0 standards, with advanced MES manufacturing execution systems, Internet-of-Things technology, real-time production monitoring systems and a transparent manufacturing cycle, delivering the promise of a digital smart factory.
Xpeng has accumulated extensive experience through the production of the G3 smart SUV at the Zhengzhou plant, a partnership with Haima Automobile. By bringing manufacturing in-house, Xpeng is enhancing the autonomy, robustness, flexibility, cost-efficiency and intelligence of its vehicle production.
“The combination of end-to-end closed-loop R&D, smart manufacturing and quality customer services is our key differentiator. Today marks another milestone in Xpeng’s 6-year history, setting a solid foundation in pursuing our vision as a leader in the intelligent EV market,” Chairman He concluded.
For videos and images please visit:
https://drive.google.com/open?id=1mjds6n51HszTF5YhDcbaViucSwLjeiio
About XPENG Motors
Xpeng Motors is a leading Chinese electric vehicle company that designs and manufactures automobiles that are seamlessly integrated with the Internet and utilize the latest advances in artificial intelligence. The company's initial backers include its Chairman & CEO, He Xiaopeng, who’s also the co-founder of UCWeb Inc. and a former Alibaba executive. Established in 2014, Xpeng Motors has a senior management team with diverse backgrounds, including Co-founders Henry Xia and He Tao, both former senior executives at Guangzhou Auto with expertise in innovative automotive technology and R&D, and Vice Chairman & President Brian Gu, former Chairman of Asia Pacific Investment Banking at J.P. Morgan. It has received funding from strategic investors Alibaba Group and Xiaomi Corporation, as well as other prominent Chinese and international investors including IDG Capital, Morningside Venture Capital, GGV Capital and Primavera Capital. The company launched its first production model, the G3 SUV, in Dec 2018, and will launch its second production model, the P7 electric sports sedan, in April 2020 with deliveries to Chinese customers in Q2 2020. Xpeng Motors is headquartered in Guangzhou, China with offices in Beijing, Shanghai, Silicon Valley and San Diego in the U.S. and manufacture centers in Zhengzhou and Zhaoqing. For more information, please visit the official website: https://en.xiaopeng.com/
Follow us on social media for latest Xpeng news:
Facebook
Twitter
LinkedIn
YouTube
Instagram
View source version on businesswire.com: https://www.businesswire.com/news/home/20200519005994/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom